

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549**

FORM 8-K

**CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934**

Date of Report (Date of earliest event reported): **June 5, 2008**

AngioDynamics, Inc.

(Exact Name of Registrant as Specified in Charter)

Delaware
(State or Other Jurisdiction
of Incorporation)

000-50761
(Commission File
Number)

11-3146460
(IRS Employer
Identification No.)

603 Queensbury Avenue, Queensbury, New York 12804
(Address of Principal Executive Offices) (Zip Code)

(518) 798-1215
(Registrant's telephone number, including area code)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 - Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 - Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))
 - Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4 (c))
-

Item 2.02 – Results of Operations and Financial Condition.

On June 5, 2008, AngioDynamics, Inc. (the “Company”) issued a press release, a copy of which is attached as Exhibit 99.1, announcing its preliminary net sales for its fiscal fourth quarter and fiscal year 2008. The Company expects to release financial results for the fiscal fourth quarter and fiscal year 2008 after the close of the financial markets on July 24 and will host an investment community conference call on the same day.

The information set forth in Item 2.02 of this Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the Exchange Act), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such a filing.

Item 5.02 - Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On June 5, 2008, John Soto resigned from his position as Senior Vice President of Global Sales, effective June 6, 2008.

Forward-Looking Statements

This document and its attachments include "forward-looking statements" intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Investors can identify these statements by the fact that they do not relate strictly to historical or current facts. These statements contain words such as "expect," "reaffirm," "anticipate," "plan," "believe," "estimate," "may," "will," "predict," "project," "might," "intend," "potential," "could," "would," "should," "estimate," "seek," "continue," "pursue," or "our future success depends," or the negative or other variations thereof or comparable terminology, are intended to identify such forward-looking statements. In particular, they include statements relating to, among other things, future actions, strategies, future performance, future financial results of the Company. These forward-looking statements are based on current expectations and projections about future events.

Investors are cautioned that forward-looking statements are not guarantees of future performance or results and involve risks and uncertainties that cannot be predicted or quantified and, consequently, the actual performance or results of the Company may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, but are not limited to, the factors described from time to time in the Company's reports filed with the SEC, including the Company's Form 10-K for the fiscal year ended June 2, 2007 and Form 10-Q for the period ended February 29, 2008, financial community and rating agency perceptions of the Company; the effects

of economic, credit and capital market conditions on the economy in general, and on medical device companies in particular; domestic and foreign health care reforms and governmental laws and regulations; third-party relations and approvals, technological advances and patents attained by competitors; and challenges inherent in new product development, including obtaining regulatory approvals. In addition to the matters described above, the ability of the Company to consummate the purchase of the Diomed businesses previously disclosed, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, the outcome of pending patent litigation, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, and the effects on pricing from group purchasing organizations and competition, may affect the actual results achieved by the Company.

Any forward-looking statements are made pursuant to the Private Securities Litigation Reform Act of 1995 and, as such, speak only as of the date made. The Company disclaims any obligation to update the forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements which speak only as of the date stated, or if no date is stated, as of the date of this document.

Item 9.01 – Financial Statements and Exhibits.

(d) *Exhibits.*

Exhibit No. Description

99.1 Press Release dated June 5, 2008.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ANGIODYNAMICS, INC.
(Registrant)

Date: June 5, 2008

By: /s/ D. Joseph Gersuk
D. Joseph Gersuk
Chief Financial Officer

EXHIBIT INDEX

<u>Exhibit No.</u>	<u>Description</u>
99.1	Press Release dated June 5, 2008.

FOR IMMEDIATE RELEASE

Company Contact:

[AngioDynamics, Inc.](#)
D. Joseph Gersuk, CFO
(800) 772-6446 x1608
jgersuk@AngioDynamics.com

Investor Relations Contacts:

[EVC Group, Inc.](#)
Doug Sherk / Donald Takaya
(415) 896-6820
dsherk@evcgroup.com
dtakaya@evcgroup.com

Media Contact:

[EVC Group, Inc.](#)
Chris Gale
(646) 201-5431
cgale@evcgroup.com

**AngioDynamics Reports Preliminary Net Sales
For Fiscal Fourth Quarter
and Fiscal Year 2008**

QUEENSBURY, NY (June 5, 2008) – AngioDynamics, Inc. (**NASDAQ: ANGO**), a leading provider of innovative medical devices used by interventional radiologists, nephrologists and surgeons for the minimally invasive treatment of cancer and peripheral vascular disease, today reported preliminary, unaudited net sales results for its fiscal fourth quarter and fiscal year ended May 31, 2008, both of which are in-line with the Company’s guidance provided in connection with the release of its fiscal third quarter results. The Company also announced that John Soto has resigned from his position as Senior Vice President of Global Sales and has accepted the position of Managing Director with a company in his home country, the United Kingdom.

The Company currently expects net sales for the fiscal fourth quarter of 2008 to be approximately \$46.7 million, which would represent an increase of approximately 14% over fiscal fourth quarter 2007 net sales of \$40.9 million. Fiscal year 2008 net sales is expected to be approximately \$166.4 million, which would represent an increase of approximately 48% over fiscal year 2007 net sales of \$112.2 million. Net sales in fiscal year 2008 includes a full year of sales from RITA Medical Systems which AngioDynamics acquired on January 29, 2007. The Company expects to release financial results for the fiscal fourth quarter and fiscal year 2008 after the close of the financial markets on July 24 and will host an investment community conference call on the same day.

“We executed well during the fourth quarter and made progress toward implementing our growth strategy” said Eamonn Hobbs, President and CEO of AngioDynamics. “With our recent agreement to acquire Diomed’s U.S. and U.K. assets, an additional license to certain patents from our settlement with VNUS and the closing of our acquisition of Oncobionic, we believe the Company is well-positioned for continued growth in fiscal 2009 and beyond. We plan to provide fiscal 2009 guidance shortly after we close the Diomed acquisition, which is expected to take place on June 16.”

“We also want to thank John Soto for his contributions during the past year. Family obligations prevented him from permanently relocating to the United States and we wish him the best of success with his new position in the United Kingdom. We are in the process of transitioning John’s responsibilities to several others within our organization as well as preparing to integrate the Diomed acquisition into our operations,” added Mr. Hobbs.

On June 3, 2008, AngioDynamics announced the settlement of litigation with VNUS Medical, which will result in an after-tax charge of approximately \$4.2 million, or \$0.17 per share, in the fiscal fourth quarter.

This press release contains preliminary, unaudited net sales for the fiscal fourth quarter and fiscal year 2008. Because the net sales results described in this release are preliminary, these results remain subject to change to reflect necessary corrections or adjustments or changes in accounting estimates that are identified prior to the time that we release our audited results. Actual results may vary from the results presented in this release.

About AngioDynamics

AngioDynamics, Inc. is a leading provider of innovative medical devices used by interventional radiologists, surgeons, and other physicians for the minimally invasive treatment of cancer and peripheral vascular disease. The Company's diverse product line includes market-leading radiofrequency ablation systems, vascular access products, angiographic products and accessories, dialysis products, angioplasty products, drainage products, thrombolytic products, embolization products and venous products. More information is available at www.angiodynamics.com.

Safe Harbor

The statements made in this document include forward-looking statements intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. Words such as "expects," "reaffirms" "intends," "anticipates," "plans," "believes," "seeks," "estimates," or variations of such words and similar expressions, are intended to identify such forward-looking statements. Investors are cautioned that actual events or results may differ from the Company's expectations. In addition to the matters described above, the ability of the Company to consummate the purchase of the Diomed businesses previously disclosed, the ability of the Company to develop its products, future actions by the FDA or other regulatory agencies, results of pending or future clinical trials, overall economic conditions, general market conditions, market acceptance, foreign currency exchange rate fluctuations, the effects on pricing from group purchasing organizations and competition, as well as the risk factors listed from time to time in the SEC filings of AngioDynamics, Inc., including but not limited to its Annual Report on Form 10-K for the year ended June 2, 2007, may affect the actual results achieved by the Company. The Company does not assume any obligation to publicly update or revise any forward-looking statements for any reason.

###